European Medicines Agency validates Bristol Myers Squibb's Opdivo and Yervoy application for first-line MSI-H/dMMR metastatic colorectal cancer treatment.
Bristol Myers Squibb's application for Opdivo and Yervoy as first-line treatment for MSI-H or dMMR metastatic colorectal cancer has been validated by the European Medicines Agency (EMA). The validation is based on the CheckMate-8HW study, which showed significant improvement in progression-free survival with the combination therapy compared to chemotherapy. The submission is now in EMA's centralized review process.
May 06, 2024
3 Articles